Source: Bloomberg, 2:44

Oracle (ORCL) just delivered a stronger than expected fiscal third quarter, with cloud and AI infrastructure revenues helping lift results and push its contracted backlog higher, easing earlier worries about heavy data center spending. The earnings beat and higher AI driven backlog arrived alongside a sharp 1 day share price return of 9.18%, even though the 90 day share price return of a 17.97% decline and year to date share price return of a 16.65% decline show momentum had cooled ahead of the release. A 1 year total shareholder return of 9.20% and 5 year total shareholder return of 163.78% highlight how long term holders have still been rewarded through price gains and dividends. If Oracle’s AI push has caught your eye, this can be a useful moment to look across the sector and see how other potential winners stack up in our . With Oracle trading at $163.12, screens flag a value score of 4 and data indicating around a 39% intrinsic discount and roughly 52% discount to analyst targets. The key question is whether this represents real mispricing or whether expectations for future growth are already fully reflected in the price. Advertisement Most Popular Narrative: 58.2% Undervalued Oracle’s latest close at $163.12 sits well below a narrative fair value of $389.81, a gap that raises big questions about how far this AI story could run. The story of Oracle’s transformation is a narrative of strategic repositioning that has culminated in the company emerging as an indispensable infrastructure partner for the world’s most demanding Artificial Intelligence (AI) workloads. This strategic shift, defined by massive infrastructure investment, a landmark partnership with OpenAI, and the rise of colossal superclusters, has driven an unprecedented surge in its contract backlog, fundamentally reshaping Oracle’s long-term growth trajectory and competitive landscape. Want to see what sits behind that oversized gap between price and fair value? According to TickerTickle, the valuati...

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo

PeopleImages/iStock via Getty Images In my last article, "Can Amgen Sustain Its Rally In 2026" , I focused mainly on Amgen's Q3 results ( AMGN ) and the efficacy of MariTide in the Phase 2 trial [ NCT05669599 ]. I also talked about the reasons why, in my opinion, soft demand for its osteoporosis franchise's flagship, called Prolia [ denosumab ], is no longer creating considerable pressure on AMGN stock. But what exciting things have happened in the last few months? And why am I continuing to cover Amgen with a 'Buy' rating even though its shares have risen 19.1% over the past four months? And first, I will note the dry numbers. Its revenue rose 8.6% year-over-year to $9.87 billion , beating Wall Street analysts' expectations by $406.1 million. Meanwhile, Amgen's non-GAAP EPS also came in well above the consensus forecast, as in the past six quarters, but this time by $0.56 . Source: Seeking Alpha Also, on February 12 , the EC approved Uplizna [inebilizumab] for the treatment of certain people suffering from a neuromuscular disorder called gMG [ generalized myasthenia gravis ]. And, given the article in PMC, its prevalence ranges from 150 to 200 cases per million people in Europe. By the way, sales of Uplizna were $233 million for the three months ended December 31, up 130.7% YoY and also beat my 'base case' scenario by $23 million, despite competition from AstraZeneca's Soliris/Ultomiris ( AZN ) and argenx's Vyvgart/Vyvgart Hytrulo ( ARGX ). I believe the strong performance of this CD19-directed cytolytic antibody is primarily due to increased demand for the treatment of IgG4-RD patients, as well as its approval on December 11 last year for gMG. Source: graph was made by Author based on the financial reports of Amgen Now, let's talk about Amgen's osteoporosis franchise. Evenity offsets the decline in demand for denosumab As you may know, Amgen is one of the leaders in the metabolic bone diseases market, but the loss of exclusivity for Prolia/Xgeva in early 2025 has ...

Investors in Ford Motor Co. (Symbol: F) saw new options begin trading today, for the May 1st expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the F options chain for the new May 1st contracts and identified one put and one call contract of particular interest. The put contract at the $11.50 strike price has a current bid of $1.66. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $11.50, but will also collect the premium, putting the cost basis of the shares at $9.84 (before broker commissions). To an investor already interested in purchasing shares of F, that could represent an attractive alternative to paying $12.06/share today. Because the $11.50 strike represents an approximate 5% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 63%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 14.43% return on the cash commitment, or 105.37% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for Ford Motor Co., and highlighting in green where the $11.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $13.00 strike price has a current bid of $1.57. If an investor was to purchase shares of F stock at the current price level of $12.06/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $13.00. Considering the call seller will also collect the premi...

tawatchaiprakobkit/iStock via Getty Images Futu's ( FUTU ) stock declined even as the online brokerage reported a beat in its quarterly earnings , as depreciation of clients' Hong Kong stock holdings weighed on client assets. Shares were 4.32% lower to $146.04 during Thursday morning trading. The Hong Kong-based company reported Q4 non-GAAP EPADS of $3.07, which beats by $0.02, and revenue of $827.2M (+45.0% Y/Y), which beats by $19.77M. "Net asset inflow remained robust in the fourth quarter, but depreciation of clients' Hong Kong stock holdings weighed on client assets," said CEO Leaf Hua Li. " Total client assets were HK$1.23 trillion as of quarter end, up 65.9% year-over-year and flat quarter-over-quarter," the CEO noted. "Total trading volume hit a record HK$3.98 trillion, up 37.8% year-over-year and 2.0% quarter-over-quarter," said Li. "U.S. stock trading volume grew 17.1% sequentially to HK$3.04 trillion, primarily driven by heightened client interests in companies across the AI value chain," he said. "Hong Kong stock turnover declined 31.0% quarter-over-quarter to HK$821.1B amid subdued investor interests in China technology names during the second-half drawdown," he noted. For the quarterly revenue, brokerage commission, and handling charge income grew 34.6% year-over-year to $355.9M. Interest income increased 50.2% to $390.3M, while other income was up 78.7% to $81.0M. More on Futu Holdings Why Futu Has Strong Upside For 2026 Futu: A Robinhood-Style Platform With A Notable Valuation Discount Futu (FUTU): Is The Triple-Digit Momentum Sustainable? | 2-Minute Analysis Futu Holdings Non-GAAP EPADS of $3.07 beats by $0.02, revenue of $827.2M beats by $19.77M Seeking Alpha’s Quant Rating on Futu Holdings

cemagraphics/iStock via Getty Images The S&P 500 ( SPX ) has reverted back to its mean. We can say that because the S&P 500 has experienced a relatively stable period of order since the end of the fourth quarter of 2023. We know that's the case because the variation of stock prices with respect to the mean trend curve established from the relationship between stock prices and their trailing year dividends per share can be generally described by a normal distribution . That in itself is remarkable because stock prices are very much not normal , even when they behave in an orderly manner. When you map their variation onto a chart with zones that align with significant reference points for a normal bell curve from statistics, you'll find both too many points within one standard deviation of the mean and too many points outside the zones where they would be expected to be found 99.8% of the time if that variation was really normally distributed. But that doesn't mean we can't use the tools built for doing statistical analysis to track an index like the S&P 500 when such a period of order exists in the stock market. The following chart deploys those tools and finds that as of the close of trading on March 11, 2026, the level of the S&P 500 is just a short distance from its central mean trendline. Which is to say the level of the S&P 500 has finally returned to its established mean after having run above it since early September 2025. This is an almost textbook example of what " reverting to the mean " really means where stock prices are concerned. But in case you're wondering what it means when stock prices move outside the outer limits described by this kind of analysis, where order really does break down (as opposed to simply being the result of statistical outliers in a continuing trend like what happened back in April 2025), the ultimate textbook example involves the ultimate sell signal . Original Post Editor's Note: The summary bullets for this article were chosen ...

Novo Nordisk (NVO 0.73%) has faced several headwinds over the past two years. The company suffered clinical setbacks while losing market share to its biggest competitor, Eli Lilly, in the weight-loss drug space. Another issue it had to contend with was that some online health platforms were selling compounded versions of its famous weight loss and diabetes drug, semaglutide (the active ingredient in Wegovy and Ozempic), at much lower prices, and even outside of the legally allowed exemption for doing so, that is, when there is an officially recognized shortage of the medicine. However, Novo Nordisk recently reached an agreement with one of the leading digital health platforms that sold compounded semaglutide: Hims & Hers (HIMS 2.94%). Let's look into the details of this deal and decide whether it makes Novo Nordisk's shares more attractive. If you can't beat them, join them Shortages aside, Novo Nordisk's GLP-1 products haven't always been affordable for patients. That's why many turned to platforms like Hims & Hers, which offered non-FDA (U.S. Food and Drug Administration) approved versions of these medicines at reduced prices. Of course, this meant lower sales volume and revenue for Novo Nordisk. That's why the Denmark-based pharmaceutical leader had previously announced a patent lawsuit against Hims & Hers. However, the drugmaker has now changed its strategy. Novo Nordisk will partner with Hims & Hers to sell the branded, FDA-approved versions of its famous drug on the telehealth platform at the same reduced self-pay prices it offers elsewhere, including on its own platform, NovoCare. This move arguably solves several problems for Novo Nordisk. Partnering with Hims & Hers, a leading distributor of compounded semaglutide, will allow the company to undercut sales of the cheap knock-offs and redirect demand toward the branded, approved version of the medicine, since the main price advantage of the former is partly gone, while the risk of taking non-FDA-approved ther...

Key Points Novo Nordisk will partner with Hims & Hers to sell affordable branded semaglutide. This will decrease competition from compounded versions of the drug. Beyond this deal, there are several reasons to buy Novo Nordisk stock. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) has faced several headwinds over the past two years. The company suffered clinical setbacks while losing market share to its biggest competitor, Eli Lilly, in the weight-loss drug space. Another issue it had to contend with was that some online health platforms were selling compounded versions of its famous weight loss and diabetes drug, semaglutide (the active ingredient in Wegovy and Ozempic), at much lower prices, and even outside of the legally allowed exemption for doing so, that is, when there is an officially recognized shortage of the medicine. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » However, Novo Nordisk recently reached an agreement with one of the leading digital health platforms that sold compounded semaglutide: Hims & Hers (NYSE: HIMS). Let's look into the details of this deal and decide whether it makes Novo Nordisk's shares more attractive. If you can't beat them, join them Shortages aside, Novo Nordisk's GLP-1 products haven't always been affordable for patients. That's why many turned to platforms like Hims & Hers, which offered non-FDA (U.S. Food and Drug Administration) approved versions of these medicines at reduced prices. Of course, this meant lower sales volume and revenue for Novo Nordisk. That's why the Denmark-based pharmaceutical leader had previously announced a patent lawsuit against Hims & Hers. However, the drugmaker has now changed its strategy. Novo Nordisk will partner with Hims & Hers to sell the branded, FDA-approved versions of its famous drug on the tele...

Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options become available today, for the May 1st expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the BMY options chain for the new May 1st contracts and identified one put and one call contract of particular interest. The put contract at the $54.00 strike price has a current bid of $1.79. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $54.00, but will also collect the premium, putting the cost basis of the shares at $52.21 (before broker commissions). To an investor already interested in purchasing shares of BMY, that could represent an attractive alternative to paying $58.77/share today. Because the $54.00 strike represents an approximate 8% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 76%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 3.31% return on the cash commitment, or 24.20% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for Bristol Myers Squibb Co., and highlighting in green where the $54.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $63.00 strike price has a current bid of $1.28. If an investor was to purchase shares of BMY stock at the current price level of $58.77/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $63.00. Considering the call sell...

Investors in Pfizer Inc (Symbol: PFE) saw new options become available today, for the May 1st expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the PFE options chain for the new May 1st contracts and identified one put and one call contract of particular interest. The put contract at the $24.00 strike price has a current bid of $1.43. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $24.00, but will also collect the premium, putting the cost basis of the shares at $22.57 (before broker commissions). To an investor already interested in purchasing shares of PFE, that could represent an attractive alternative to paying $26.96/share today. Because the $24.00 strike represents an approximate 11% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 74%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 5.96% return on the cash commitment, or 43.50% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for Pfizer Inc, and highlighting in green where the $24.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $31.50 strike price has a current bid of $1.03. If an investor was to purchase shares of PFE stock at the current price level of $26.96/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $31.50. Considering the call seller will also collect the pr...

Investors in Coca-Cola Co (Symbol: KO) saw new options begin trading today, for the May 1st expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the KO options chain for the new May 1st contracts and identified one put and one call contract of particular interest. The put contract at the $77.00 strike price has a current bid of $1.68. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $77.00, but will also collect the premium, putting the cost basis of the shares at $75.32 (before broker commissions). To an investor already interested in purchasing shares of KO, that could represent an attractive alternative to paying $77.59/share today. Because the $77.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 56%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 2.18% return on the cash commitment, or 15.93% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for Coca-Cola Co, and highlighting in green where the $77.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $78.00 strike price has a current bid of $1.59. If an investor was to purchase shares of KO stock at the current price level of $77.59/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $78.00. Considering the call seller will also collect the premiu...

In early trading on Thursday, shares of CF Industries Holdings topped the list of the day's best performing components of the S&P 500 index, trading up 8.2%. Year to date, CF Industries Holdings registers a 68.0% gain. And the worst performing S&P 500 component thus far on the day is Dollar General, trading down 7.4%. Dollar General is showing a gain of 1.0% looking at the year to date performance. Two other components making moves today are Carnival, trading down 4.8%, and Mosaic, trading up 4.9% on the day. VIDEO: S&P 500 Movers: DG, CF The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo

Investors in Conagra Brands Inc (Symbol: CAG) saw new options become available today, for the May 1st expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the CAG options chain for the new May 1st contracts and identified one put and one call contract of particular interest. The put contract at the $16.50 strike price has a current bid of $1.79. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $16.50, but will also collect the premium, putting the cost basis of the shares at $14.71 (before broker commissions). To an investor already interested in purchasing shares of CAG, that could represent an attractive alternative to paying $16.73/share today. Because the $16.50 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 58%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 10.85% return on the cash commitment, or 79.19% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for Conagra Brands Inc, and highlighting in green where the $16.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $19.00 strike price has a current bid of $1.45. If an investor was to purchase shares of CAG stock at the current price level of $16.73/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $19.00. Considering the call seller will als...

穆杰塔巴说，必须强调的是，无论如何伊朗都将向敌人索取赔偿。“若其拒绝，我们将按照适当的程度没收其资产；若无法没收，则以同等程度摧毁其资产。' 穆杰塔巴在声明中说，民众要求继续实施有效且令敌人痛苦的防御策略，并强调，“封锁霍尔木兹海峡的战略杠杆必须持续运用”。图：IC PHOTO 【财新网】 德黑兰当地时间3月12日下午5时，现年56岁的伊朗新任最高领袖穆杰塔巴·哈梅内伊发表了他当选最高领袖以来的首份声明。 穆杰塔巴在声明中说，民众要求继续实施有效且令敌人痛苦的防御策略，并强调，“封锁霍尔木兹海峡的战略杠杆必须持续运用”。 穆杰塔巴还说，“我们还研究了在敌人经验匮乏且极易受创的其他战线，展开攻势的可能性。若战时局势持续，我们将根据实际需要启动这些战线。" 穆杰塔巴也向伊朗战斗人员致以诚挚谢意——“当傲慢阵营的头目们无端袭击我国和挚爱家园时，正是他们以雷霆之势阻断敌军的进路，粉碎了敌人企图支配或分裂我国的妄想。"

标普500指数跌幅扩大至1.3%，道指下跌675点、跌幅超过1.4%，纳指跌约1.7%，半导体指数跌超3.3%，银行指数跌约2.8%，生物科技指数跌超2.2%。 欧洲STOXX 600指数跌幅扩大至1%，刷新日低。 风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。

格隆汇3月12日｜欧洲斯托克600指数延续跌势，跌幅扩大至1%，触及当日低点。

路透调查的经济学家预计，美联储今年将于6月首次降息，尽管美以对伊战争可能扰乱能源市场，推高本已居高不下的通胀，受访者仍坚持这一预测。 全球油价已上涨约40%，带动对利率更为敏感的两年期美债收益率上行近30个基点，利率期货市场的预期也已推迟至9月才出现年内首次降息，第二次降息的可能性已基本被市场排除。 在2月底战争爆发前，通胀率已远超美联储2%的目标，加上2月非农就业岗位意外减少9.2万个，3月6日至12日的调查显示，全部96位受访经济学家均认为美联储将在3月18日维持3.50%-3.75%的利率区间不变。 在上月调查中，略低于四分之三的受访者预期上述结果。 约三分之二的受访经济学家（96人中有63人）预计美联储将在下季度将利率区间降至3.25%-3.50%，最可能的时间点是6月——即主席鲍威尔5月任期结束后。 美国总统特朗普已提名沃什接任美联储主席，并多次批评鲍威尔降息步伐过慢。 野村证券美国高级经济学家Jeremy Schwartz表示：“很清楚，沃什已让总统相信他将尝试去做什么，我们也必须把这点纳入预测……但问题在于，委员会内部的动态及数据是否允许他付诸实施。” “今年他大概能推动一两次降息。” “伊朗冲突推高全球能源价格。这将在一定程度上影响整体通胀，也可能传导至核心通胀组成部分。与此同时，劳动力市场基本面虽不强劲，但未见恶化，这种局面使美联储无需采取更被动的应对姿态。” 对年底利率水平，受访者并无共识；但调查中值显示，11月中期选举前将降息两次。 近40%的受访经济学家预计今年仅降息一次或不降息，这一占比几乎是预测将降息三次或以上的两倍。 调查中值显示，美联储青睐的通胀指标——个人消费支出（PCE）物价指数——今年上半年平均涨幅预计为2.8%，2026年全年为2.7%，较上月的预测略有上升。 PNC Financial Services Group首席经济学家Gus Faucher表示：“通胀已五年未达到2%目标。短期内通胀反而可能攀升．．．当前通胀风险大于劳动力市场风险。” 目前美国失业率为4.4%，受访者预计今年将持稳。 在回答附加问题的37位经济学家中，近80%（29人）认为，美联储更可能比他们预期更长时间维持利率不变，而非更快降息。 强劲的经济增长前景同样削弱了政策支持的必要性。受访者预计今年美国经济将以每季度2.1%-2.5%的速度扩张，快于上季度...

Looking at the universe of stocks we cover at Dividend Channel , on 3/13/26, NexPoint Residential Trust Inc (Symbol: NXRT) will trade ex-dividend, for its quarterly dividend of $0.53, payable on 3/31/26. As a percentage of NXRT's recent stock price of $26.19, this dividend works out to approximately 2.02%, so look for shares of NexPoint Residential Trust Inc to trade 2.02% lower — all else being equal — when NXRT shares open for trading on 3/13/26. In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from NXRT is likely to continue, and whether the current estimated yield of 8.09% on annualized basis is a reasonable expectation of annual yield going forward. The chart below shows the one year performance of NXRT shares, versus its 200 day moving average: Looking at the chart above, NXRT's low point in its 52 week range is $26 per share, with $40.78 as the 52 week high point — that compares with a last trade of $26.54. According to the ETF Finder at ETF Channel, NXRT makes up 3.88% of the SRH REIT Covered Call ETF (Symbol: SRHR) which is trading lower by about 0.9% on the day Thursday. (see other ETFs holding NXRT). In Thursday trading, NexPoint Residential Trust Inc shares are currently off about 0.5% on the day. Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Looking at the universe of stocks we cover at Dividend Channel , on 3/16/26, Red Rock Resorts Inc (Symbol: RRR) will trade ex-dividend, for its quarterly dividend of $0.26, payable on 3/31/26. As a percentage of RRR's recent stock price of $57.79, this dividend works out to approximately 0.45%. In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from RRR is likely to continue, and whether the current estimated yield of 1.80% on annualized basis is a reasonable expectation of annual yield going forward. The chart below shows the one year performance of RRR shares, versus its 200 day moving average: Looking at the chart above, RRR's low point in its 52 week range is $35.09 per share, with $68.99 as the 52 week high point — that compares with a last trade of $57.94. According to the ETF Finder at ETF Channel, RRR makes up 3.82% of the Baron First Principles ETF (Symbol: RONB) which is trading lower by about 0.3% on the day Thursday. (see other ETFs holding RRR). In Thursday trading, Red Rock Resorts Inc shares are currently off about 2% on the day. Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Looking at the universe of stocks we cover at Dividend Channel , on 3/13/26, Leggett & Platt, Inc. (Symbol: LEG) will trade ex-dividend, for its quarterly dividend of $0.05, payable on 4/15/26. As a percentage of LEG's recent stock price of $10.32, this dividend works out to approximately 0.48%. In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from LEG is likely to continue, and whether the current estimated yield of 1.94% on annualized basis is a reasonable expectation of annual yield going forward. The chart below shows the one year performance of LEG shares, versus its 200 day moving average: Looking at the chart above, LEG's low point in its 52 week range is $6.475 per share, with $13 as the 52 week high point — that compares with a last trade of $10.27. According to the ETF Finder at ETF Channel, LEG makes up 2.37% of the Towle Value ETF (Symbol: TCV) which is trading higher by about 1% on the day Thursday. (see other ETFs holding LEG). In Thursday trading, Leggett & Platt, Inc. shares are currently off about 1.4% on the day. Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In the three decades between 1993 and 2024, measles in the US was relatively rare—a few hundred cases each year, at most. But suddenly, the disease has become so entrenched in American life that it sometimes fails to make headlines when a new outbreak erupts. As of March 2026, measles has been continuously circulating around the US for more than a year, starting with an outbreak in Texas that lasted from January to August 2025. Before that outbreak was declared over , an outbreak on the Utah and Arizona border began in August and is ongoing. An outbreak in South Carolina began in September, drastically increased in January 2026, and continues. Thirty states have had measles cases this year ; 47 have seen cases since the start of 2025. Health officials across the US have confirmed 1,300 infections already this year as of March 6, putting the country on track to surpass 2025’s numbers, which were the highest in 35 years. Read full article Comments

格隆汇3月12日｜美国上周EIA天然气库存变动减少380亿立方英尺，前值减少1320亿立方英尺。

米兰检察官已要求对亚马逊欧洲部门及其四名经理进行审判，他们涉嫌逃税价值约12亿欧元（13.8亿美元），两名直接了解此事的消息人士周四表示。 此举在意大利的此类案件中史无前例，因为亚马逊在12月同意向意大利税务局支付包括利息在内的5.27亿欧元，以解决税务纠纷。 在以前所有涉及其他国际集团的案件中，一旦达成和解并支付了款项，检察官就会通过认罪协议或撤销案件的方式结束相关的刑事调查。 但这一次，米兰检察官不同意税务局的做法，决定继续调查，并要求将嫌疑人送审。 亚马逊公司没有立即发表评论。 责任编辑：刘明亮

据知情人士透露，欧盟委员会考虑放宽碳排放配额供应规则，并允许提供更多国家援助，以作为应急方案的一部分来遏制电价飙升。 因讨论未公开信息而要求匿名的知情人士表示，欧盟委员会还在研究是否暂时放宽企业获得免费排放配额的规定，同时允许降低电网费用和能源税。 欧盟委员会将于3月19日在布鲁塞尔举行的欧盟领导人峰会上提交相关选项。目前方案仍可能调整。此次峰会议程已被持续发酵的伊朗战争所主导，冲突扰乱了油气运输并推高能源价格。 欧盟委员会拒绝置评。 责任编辑：李肇孚

Image source: The Motley Fool. March 10, 2026 Call participants Chief Executive Officer — Kenneth Romanzi Chief Financial Officer — Shane Jones General Counsel — Nathan Brower Need a quote from a Motley Fool analyst? Email [email protected] Takeaways Net Sales -- $123.8 million for the quarter, a 5% year-over-year increase, driven by North America and Europe, and marking the company's strongest fourth quarter on record. -- $123.8 million for the quarter, a 5% year-over-year increase, driven by North America and Europe, and marking the company's strongest fourth quarter on record. Full-Year Net Sales -- $480.1 million, up 6%, and surpassing the high end of the latest guidance range. -- $480.1 million, up 6%, and surpassing the high end of the latest guidance range. North America -- Quarterly sales rose 6% to $37.4 million, while digital channel revenue soared 47% compared to prior year. -- Quarterly sales rose 6% to $37.4 million, while digital channel revenue soared 47% compared to prior year. Asia Pacific -- Quarterly sales decreased 1% to $55.7 million, attributed to a challenging comparison and 21% sales growth reported in the year-ago period. -- Quarterly sales decreased 1% to $55.7 million, attributed to a challenging comparison and 21% sales growth reported in the year-ago period. Europe -- Quarterly sales increased 18% to $25.2 million, led by 23% growth in Eastern Europe in local currency, with improved product availability. -- Quarterly sales increased 18% to $25.2 million, led by 23% growth in Eastern Europe in local currency, with improved product availability. Gross Margin -- Improved by 55 basis points to 72.5%, primarily from gross margin initiatives and favorable market mix. -- Improved by 55 basis points to 72.5%, primarily from gross margin initiatives and favorable market mix. SG&A Expenses -- $48.4 million for the quarter, up from $43.7 million, rising to 39.1% of sales due to higher digital ad spend, sales-related variable costs, and one-time exp...

WTI原油期货涨超9%，至接近94美元的水平，逼近亚太早盘刷新的日高94.60美元。 上期所燃油主力合约涨超4%，报4874元人民币/吨。原油主力合约大涨7%，报762.4元/桶。 美军杰拉尔德·R·福特号航空母舰发生火情，与作战无关。 风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。

Another one: Chuwi CoreBook Plus laptop also has a fake AMD Ryzen Mezha